Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review

Osimertinib is a third-generation, irreversible mutant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Osimertinib is currently the first line drug recommended by National Comprehen...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Chengyang, Yang, Xueying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047874/
https://www.ncbi.nlm.nih.gov/pubmed/35494059
http://dx.doi.org/10.3389/fonc.2022.834585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047874/
https://www.ncbi.nlm.nih.gov/pubmed/35494059
http://dx.doi.org/10.3389/fonc.2022.834585

Ejemplares similares